Turn fragmented scientific evidence into prioritized drug discovery decisions.

SynAgentics Biosciences is building AI4Science workflows that help biotech teams synthesize evidence, compare candidates, identify development risks, and plan the next steps with confidence.

Request investor deck

See platform

Early Platform Demonstration

01

Ask

Research question

What evidence supports HER2 as a target for ADC therapies in solid tumors?

02

Collect Evidence

Relevant publications 245 Results

  • HER2-targeted ADCs in breast and gastric cancer

  • Novel linker technologies for HER2 ADCs

03

Evaluate

Observe pertinent project information

  • Evidence summary

  • Comparing evidence

  • Contradictory findings

  • Study limitations

04

Generate Hypotheses

Proposed hypotheses

Next-generation HER2 ADCs with optimized linker chemistry may improve therapeutic window in HER2-low tumors.

Rationale: strong biological basis, supporting preclinical evidence, identified research gaps

05

Output Report

Generated research report

  • Evidence summary

  • Hypothesis list

  • Key uncertainty flags

  • Recommended next steps

and testable hypotheses.
transforming scientific questions into
structured evidence
Our first AI4Science agent is
nearing completion...

Partner with us to shape the future of AI in drug discovery.

SynAgentics is opening partner conversations with biotech teams, venture studios, and strategic pharma groups building AI-first pipelines.

Request deck

Contact SynAgentics